Program
Trastuzumab
Also written as “Herceptin”, “trastuzumab [Herceptin]” and “trastuzumab”.
Its studies are mostly in Breast Neoplasms · Stomach Neoplasms · Colorectal Neoplasms · Neoplasms · Urologic Neoplasms, led by 20 companies.
Drug pageTrastuzumab: every studyMany companies study it; this page follows only the 79 they lead. All 533 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 470 open or running | phase 4since Dec 13, 2010 | May 2, 2000 | none ahead |
| Novartisits history only | 50 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Pfizerits history only | 31 open or running | phase 3since Feb 14, 2022 | Oct 20, 2005 | Dec 31, 2027phase 3 · NCT05253651 |
| Celltrionits history only | 20 open or running | phase 3since Jun 11, 2014 | Jun 11, 2014 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 2since Aug 31, 2007 | Aug 31, 2007 | none ahead |
| Jiangsu HengRui Medicineits history only | 22 open or running | phase 3since Aug 14, 2026 | Aug 17, 2025 | Oct 2027phase 2 · NCT07140393 |
| Prestige Biopharmaits history only | 20 open or running | phase 3since Dec 29, 2016 | Dec 29, 2016 | none ahead |
| Sanofiits history only | 20 open or running | phase 3since Jul 11, 2001 | Jul 11, 2001 | none ahead |
| Sarah Cannon Research Instituteits history only | 21 open or running | phase 2since Jun 27, 2007 | Jun 27, 2007 | none ahead |
| Tanvex BioPharma USAits history only | 20 open or running | phase 3since Jun 1, 2018 | Jun 1, 2018 | none ahead |
| AryoGen Pharmedits history only | 10 open or running | phase 3since Nov 21, 2017 | Nov 21, 2017 | none ahead |
| Biocadits history only | 10 open or running | phase 3since Jan 7, 2013 | Jan 7, 2013 | none ahead |
| Cogent Biosciencesits history only | 10 open or running | phase 1since Sep 14, 2018 | Sep 14, 2018 | none ahead |
| Incepta Pharmaceuticalsits history only | 10 open or running | phase 1since Jan 12, 2025 | Jan 12, 2025 | none ahead |
| Meiji Seika Pharmaits history only | 10 open or running | phase 1since Mar 27, 2014 | Mar 27, 2014 | none ahead |
| Merck | 10 open or running | phase 2since May 27, 2008 | May 27, 2008 | none ahead |
| NovoCureits history only | 10 open or running | no phasesince Feb 20, 2020 | Feb 20, 2020 | none ahead |
| Orano Medits history only | 10 open or running | phase 1since Jun 27, 2011 | Jun 27, 2011 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 1since Mar 1, 2023 | Mar 1, 2023 | none ahead |
| Viatrisits history only | 10 open or running | phase 1since Oct 29, 2015 | Oct 29, 2015 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo, Medivation LLC, a wholly owned subsidiary of Pfizer, AbbVie, Zai Lab, Nippon Kayaku, MDS Pharma Services, Mylan and Dong-A Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- May 27, 2008First study: phase 2 study in Breast NeoplasmsFirst studyNCT00687440 · 27 enrolled
- Jun 9, 2016Named trastuzumabINNProposed as its International Nonproprietary Name in WHO's List 115 · before, HD201
TargetBeta
“A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2)”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 57 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
The one study Merck leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00687440Breast Neoplasms | 2 | Completed | Oct 24, 2008 | 27 |
How it is read
Names in the registry
- “Trastuzumab”, 36 entries
- “Herceptin”, 13 entries
- “trastuzumab [Herceptin]”, 11 entries
- “trastuzumab”, 9 entries
- “HD201”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 62 studies
- Stomach Neoplasms, 7 studies
- Colorectal Neoplasms, 2 studies
- Neoplasms, 2 studies
- Urologic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.